SEC Form 4 · accession 0000899243-17-018642
Dicerna Pharmaceuticals Inc · DRNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martin I Freed
Director
Period of report
Jul 18, 2017
Accepted (ET)
Jul 20, 2017 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001399529
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (Right to Buy)F1 | $3.42 | Jul 18, 2017 | A | 25,000 | A | — | Jul 18, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1This option vests monthly over 12 months from July 11, 2017 in substantially equal monthly installments, subject to the Reporting Person's continued service to the Issuer through each such date.